Mount Sinai School

The Inner Circle acknowledges Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member

Retrieved on: 
Thursday, March 7, 2024
Theta, Overlook Medical Center, Woman, Professional, Inner circle, Doctor of Philosophy, Multimedia, MD, Georgetown University, Education, Immunotherapy, Pathology, Thomas Jefferson University, Uterine cancer, ABOG, Parent, Principal investigator, Radiation, National Cancer Institute, Women's studies, Gynecologic Oncology (journal), Health, FACOG, Oncology nursing, Brown University, Vaginal cancer, Ovarian cancer, Associate, Gestational trophoblastic disease, Women's health, Biology, Mount Sinai School, Estate (law), Delta Sigma, Research, Carol, Medication

CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies.
  • She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers.

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Retrieved on: 
Monday, February 5, 2024
ACT, Cardiomyopathy, Duchenne muscular dystrophy, Pfizer, LMNA, MD, FDA, Andexanet alfa, Georgetown University Law Center, Mount Sinai School, ATTR, Senior advisor, International Society, Private practice, UCSD, Alexion, Law, Rare disease, Georgetown Journal, Nephrology, Neurology, Civil Service (United Kingdom), Biogen, University, Development, American Heart Association, Hospital, Orthostatic hypertension, Bachelor, Reata Pharmaceuticals, International law, Professor, Disclosure, Information technology, EMA, Southern Illinois University, Therapy, Assistant, Pediatrics, Sickle cell disease, Pharmaceutical industry

“The accumulating talent bench at Lexeo has overseen some of the most transformative clinical development programs, drug approvals and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.

Key Points: 
  • “The accumulating talent bench at Lexeo has overseen some of the most transformative clinical development programs, drug approvals and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.
  • During her tenure, Dr. See Tai led the late-stage clinical development program of tafamidis for ATTR cardiomyopathy (ATTR-ACT), which achieved global regulatory approvals, and the Phase 3 LMNA dilated cardiomyopathy clinical program.
  • In addition to late-stage clinical development, Dr. See Tai was responsible for strategic clinical planning for early-stage development candidates such as those for other genetic cardiomyopathies and Duchenne Muscular Dystrophy.
  • Dr. Adler’s work has led to the development of a novel cardiovascular gene therapy candidate entering late-stage clinical development.

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Retrieved on: 
Wednesday, January 24, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Genetics, Nuclear medicine, Entrepreneurship, Artificial intelligence, Patient, Internal medicine, Research, American College of Physicians, MD, Cardio, Emory University, JACC, Innovation, University, Algorithm, Journal of Clinical Investigation, FACC, ACP, ACC, Journal, NIH, Cardiovascular disease, Bachelor of Science, Hospital, Society for Vascular Surgery, Mount Sinai School, American College, Growth, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.
  • The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion.
  • “I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee.
  • Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care.

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Retrieved on: 
Monday, December 11, 2023
Dexmedetomidine, Cardiology, Agitation, FDA, Roche, Actelion, Reata Pharmaceuticals, GSK, Pfizer, IND, Adamas, Medicine, Physician, University, Mount Sinai School, Schizophrenia, Doctor of Philosophy, MEK, Journal of Clinical Pathology, Intermittent explosive disorder, GSK plc, New product development, Caregiver, EMA, Therapy, Patient, Intelligence, Development, Senior, DSM-IV codes, Bipolar disorder, Sanofi, Royal college, Acquisition, Prostate cancer, Clinical trial, Biogen, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Key Points: 
  • Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors.
  • Prior to joining BioXcel Therapeutics, Dr. O’Neill held senior leadership roles at several leading global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline.
  • “I look forward to working with the BioXcel leadership team in continuing to address the unmet medical needs of patients and caregivers and advance the Company’s product-development goals.”

Seth L. Matarasso, MD, Begins ASDS / ASDSA Presidency

Retrieved on: 
Monday, November 27, 2023
Mentorship, Treasurer, Policy, Baylor College of Medicine, Archive, Physician, ASDS, Hope, Evidence-based medicine, Strategic planning, MD, Society, Samuel, American Academy, University, Human, Mount Sinai School, Publication, Journal, Strategy, Clinical professor, Communication

Reimagining the future by fostering member engagement in and proactively reinforcing patient safety with those in a position to determine policy on the practice of medicine.

Key Points: 
  • Reimagining the future by fostering member engagement in and proactively reinforcing patient safety with those in a position to determine policy on the practice of medicine.
  • Embracing change and hope by implementing a new strategic plan and confirming a new Executive Director.
  • Enhancing and evolving members’ unified communication as credible medical sources, educating the public, medical peers and legislators on the scope of dermatologic surgeons’ expertise.
  • “To serve as the President of the ASDS and ASDSA is one of the most significant honors of my professional career; it is humbling and a privilege,” said Dr. Matarasso during his first presidential address.

Myeloid Announces Appointment of Matthew Maurer, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, December 6, 2023
Renal cell carcinoma, Assistant, Bristol Myers Squibb, Therapy, Mechanical engineering, IND, Physician, Mount Sinai School, Biotechnology, Breast cancer, Patient, Medical Affairs Bureau, Myeloid-derived suppressor cell, Princeton University, Messenger, BSE, PARG, Myeloid tissue, Cancer, BMS, Immunotherapy, Mechanical, Pharmaceutical industry, Surgeon, Medicine, Vivo

CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.
  • as Chief Medical Officer.
  • "We are very pleased that Matt has joined Myeloid as our Chief Medical Officer.
  • Dr. Maurer received a BSE in Mechanical Engineering from Princeton University and earned his medical degree from the Mount Sinai School of Medicine.

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
Monday, November 13, 2023
Theta, Inner circle, Georgetown University, Brown University, Woman, Oncology nursing, Associate, Reproductive Sciences, Research, Radiation, Cervical cancer, Gynecologic Oncology (journal), Overlook Medical Center, Pathology, National Cancer Institute, Roswell Park, Mount Sinai School, Women's studies, Multimedia, Professional, Fellow, Thomas Jefferson University, Vaginal cancer, Medication, Health, Alpert Medical School, Vulvar cancer, ABOG, Uterine cancer, Exceptional Women in Publishing, Ovarian cancer, MD, Japanese Cancer Association, FACOG, Delta Sigma, Women's health, Atlantic Women's Colleges Conference, Carol, Volunteering, Flexner Report, Estate (law), Biology, Education, Birth control, Science, Gynaecology, Medicine, Cancer, New York (magazine), Neuroscience, Obstetrics

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders

Retrieved on: 
Thursday, November 9, 2023
UPDRS, Incidence, PD, III, Neurology, University of South Florida, Physician, Emeritus, Pramipexole, Epworth Sleepiness Scale, FRCPC, LSM, ESS, Somnolence, University, Department of Neurology, Xuanwu hospital, Mount Sinai School, NDA, Safety, Patient, PPX, Movement disorder, Dietary supplement, Pharmaceutical industry, Surveying

The study included 544 untreated patients with Parkinson’s disease who were randomized (2:2:2:1) to treatment with P2B001, its individual components (pramipexole-ER 0.6 mg or rasagiline-ER 0.75 mg), or marketed PramiER individually titrated to optimal dose (1.5-4.5 mg).

Key Points: 
  • The study included 544 untreated patients with Parkinson’s disease who were randomized (2:2:2:1) to treatment with P2B001, its individual components (pramipexole-ER 0.6 mg or rasagiline-ER 0.75 mg), or marketed PramiER individually titrated to optimal dose (1.5-4.5 mg).
  • Further, he stated that “P2B001 is a once-a-day treatment that requires no titration.
  • P2B001 was generally well tolerated and showed fewer sleep-related and dopaminergic adverse events in comparison to commercially used doses of pramipexole ER.
  • “We look forward to moving P2B001 forward towards an NDA submission to make this potential treatment option available to patients.”

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

Retrieved on: 
Monday, November 6, 2023
Haematopoietic system, Rachel Haurwitz, Multiple myeloma, Hematology, CRISPR, Jagannath, Medicine, Abstract, Icahn School of Medicine at Mount Sinai, University, Reindeer, Mount Sinai School, MD Anderson Cancer Center, Patient, University of Arkansas, Oncology, Medical device, MD

BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New York.

Key Points: 
  • BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board .
  • “We are honored to have Dr. Jagannath join our scientific advisory board.
  • “Dr.
  • We urgently need such treatment options for patients living with relapsed or refractory multiple myeloma.”

NewEdge Wealth Welcomes Michael Kramer to Stamford Office

Retrieved on: 
Monday, October 16, 2023
Personal Finance, Professional Services, Finance, Kramer, First Republic Bank, University, Biology, Culture, Rutgers University, Mount Sinai School, Entrepreneurship, Ladenburg Thalmann, CT, Financial services

NewEdge Wealth, LLC , a registered investment adviser specializing in servicing the needs of ultra high net worth families, family offices and institutional clients, announced today that Michael Kramer has joined the firm at its Stamford, CT headquarters.

Key Points: 
  • NewEdge Wealth, LLC , a registered investment adviser specializing in servicing the needs of ultra high net worth families, family offices and institutional clients, announced today that Michael Kramer has joined the firm at its Stamford, CT headquarters.
  • Kramer, along with two client service associates, will join NewEdge Wealth as a Managing Director.
  • Kramer said, "I am excited to become a part of NewEdge Wealth where I can continue to seek to help my clients grow and preserve their wealth.
  • NewEdge Wealth now has nine offices in addition to its headquarters in Stamford, Connecticut.